13F-HR: Johnson & Johnson Discloses $554M Q4 2025 Holdings

Johnson & Johnson's latest 13F filing reveals its investment portfolio for the quarter ended December 31, 2025, totaling over $554 million across 17 companies.

Summary

• Johnson & Johnson (J&J) filed its Form 13F-HR, disclosing its equity holdings for the quarter ended December 31, 2025.
• The total market value of the disclosed holdings is $554,625,589.
• The report lists 17 distinct equity positions.
• One other institutional investment manager, Johnson & Johnson Innovation JJDC, Inc., is included in this report, indicating these are likely strategic venture investments.
• All reported holdings show "DFND" investment discretion, with voting authority primarily held by the included manager, Johnson & Johnson Innovation JJDC, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive disclosure, reflecting Johnson & Johnson's ongoing strategic investment activities through its venture arm, JJDC, in the high-growth, high-risk biotechnology sector. It indicates active portfolio management aligned with long-term strategic goals.

Positives

• Disclosure of a diversified portfolio of 17 companies, primarily in the biotechnology and pharmaceutical sectors, aligning with J&J's core business and strategic investment interests.
• The significant total value of $554,625,589 demonstrates active strategic investment management.
• The inclusion of Johnson & Johnson Innovation JJDC, Inc. suggests a structured approach to venture capital and strategic investments.

Negatives

• The filing itself, as a disclosure of past holdings, does not inherently contain "negatives" in the traditional sense of financial performance.
• Many of the disclosed holdings are in early-stage or specialized biotechnology companies, which inherently carry higher risk and volatility compared to established large-cap equities.

Risks

• Investments in biotechnology and pharmaceutical companies are subject to significant regulatory risks, clinical trial failures, and intense competition.
• The value of these holdings is subject to market fluctuations and the specific performance of these often smaller-cap companies.
• Concentration in specific sectors (biotech/pharma) could expose the portfolio to sector-specific downturns.

Future Outlook

The Form 13F-HR is a historical disclosure of equity holdings and does not contain forward-looking statements or guidance from Johnson & Johnson regarding future investment strategies or market outlook.

Management Comments

• Marc Larkins, Secretary, signed the report, representing that the information is true, correct, and complete, and that he is authorized to submit it.

Industry Context

StockSavvy.ai notes that Johnson & Johnson's disclosed portfolio, heavily weighted towards biotechnology and specialized pharmaceutical companies like Adicet Bio, Contineum Therapeutics, and Fate Therapeutics, aligns with a broader industry trend of large pharmaceutical companies investing in innovative, often early-stage, biotech firms to bolster their R&D pipelines and future growth prospects. This strategy is common for established players seeking to acquire or partner with companies developing novel therapies.

Comparison to Industry Standards

• StockSavvy.ai observes that a direct comparison of this specific venture portfolio to global benchmarks or specific comparable companies is challenging without detailed performance metrics or a breakdown of investment stages. However, large pharmaceutical companies like Pfizer, Merck, and Novartis also maintain venture arms or strategic investment portfolios that similarly target emerging biotech innovations.
• For instance, Pfizer Ventures invests in early-stage companies, and Merck Global Health Innovation Fund focuses on digital health and health technology. The disclosed portfolio's composition suggests a focus on therapeutic areas relevant to J&J's broader healthcare strategy, similar to how other industry leaders strategically deploy capital into the innovation ecosystem.

Related Party Transactions

• Johnson & Johnson Innovation JJDC, Inc. is listed as an "Other Included Manager" in the report, indicating that the disclosed holdings are managed by this related entity, which is a venture capital subsidiary of Johnson & Johnson.

Stakeholder Impact

• Shareholders of Johnson & Johnson: Provides transparency into a portion of the company's strategic investment activities, which could contribute to long-term growth and pipeline development.
• Shareholders of Held Companies: Disclosure of J&J's significant stake could be seen as a vote of confidence, potentially influencing market perception and share prices of these smaller companies.
• Investment Professionals: Offers insights into J&J's investment strategy and sector focus within the healthcare industry.

Next Steps

• The filing does not specify any immediate future actions, events, or milestones for Johnson & Johnson related to these specific holdings.

Key Dates

Keywords

Johnson & Johnson, J&J, 13F, Holdings, Investment Portfolio, Biotechnology, Pharmaceuticals, Venture Capital, JJDC, SEC Filing, Equity Holdings